Rhabdomyolysis Caused by Gefitinib Overdose

Intern Med. 2022 May 15;61(10):1577-1580. doi: 10.2169/internalmedicine.8168-21. Epub 2021 Oct 26.

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subject and report a rare case of rhabdomyolysis due to an overdose of gefitinib, an EGFR-TKI.

Keywords: EGFR-TKI; overdose; rhabdomyolysis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors / genetics
  • Gefitinib / adverse effects
  • Humans
  • Lung Neoplasms* / drug therapy
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / adverse effects
  • Rhabdomyolysis* / chemically induced
  • Rhabdomyolysis* / drug therapy

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • ErbB Receptors
  • Gefitinib